publication date: Jan. 17, 2020
NCI Trials
NCI Trials for Jan. 2020
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – PEPN1812
A Phase I Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
Pediatric Early Phase Clinical Trial Network
Lamble, Adam Joseph
(206) 987-9546
Phase I/II – 10276
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Rutgers University – Cancer Institute of New Jersey LAO
Spencer, Kristen Renee
(732) 235-3378
Phase I/II – 10296
Phase Ib/II Trial of Copanlisib in Combination with Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) with PIK3CA Mutation or PTEN Mutation
University of Texas MD Anderson Cancer Center LAO
Murthy, Rashmi Krishna
(713) 792-2817
Phase I/II – 10301
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Duke University – Duke Cancer Institute LAO
Gay, Hiram Alberto
(314) 362-8516
Phase II—10302
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer
Rutgers University – Cancer Institute of New Jersey LAO
Malhotra, Jyoti
Continue reading NCI Trials for Jan. 2020To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
